Blood and clotting studies in new leukemia patients on intensive chemo
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at how blood and clotting are affected in people newly diagnosed with acute myeloid leukemia (AML) who receive a common intensive chemotherapy combination (idarubicin and cytarabine). The goal is to better understand blood-related side effects and improve care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have just been diagnosed with AML (a type of blood cancer) and have not received any chemotherapy yet.
- Your leukemia is not the M3 subtype (APL).
- You are not pregnant and do not have significant liver or kidney disease.
- You have not used blood-thinning medications (anticoagulants) recently.
- You do not have an active infection or sepsis at the time of starting treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at certain proteins in the blood (called FLT3 ligand and IL6) of people being treated for blood cancers like AML, MDS, or CMML. The goal is to understand how these proteins change during non-intensive chemotherapy, which may help doctors better personalize treatment.
This Phase 3 trial compares two chemotherapy approaches given first (induction) for people newly diagnosed with AML. It aims to find which option works better and is safer to help achieve remission.
This trial tests a combination of chemotherapy drugs (venetoclax, cladribine, cytarabine, and azacitidine) for people newly diagnosed with specific types of acute myeloid leukemia (AML) who cannot have or choose not to have standard intensive chemotherapy.
This trial tests a combination of two chemotherapy drugs (idarubicin and cytarabine) plus a newer targeted medication (venetoclax) for people with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). The goal is to see if this treatment is effective and safe as an initial therapy.
This study compares different treatment intensities for adults with acute myeloid leukemia (AML) who are less able to handle strong chemotherapy. It aims to find the best approach for people with health issues like heart or lung problems that make standard chemo riskier.
This trial tests a strong chemotherapy and radiation combo followed by a donor stem cell transplant for people with aggressive blood cancers (like AML or MDS) that haven't responded to earlier treatments or came back. It aims to help prevent the cancer from returning.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.